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http://dx.doi.org/10.1016/j.jmii.2012Background/Purpose: The emergence of carbapenem-resistant Enterobacteriaceae (CRE) is
a cause for great concern. The aim of this study was to evaluate antimicrobial susceptibility,
mechanisms of carbapenem-resistance in two members of the Enterobacteriaceae family
(Escherichia coli and Klebsiella pneumoniae), and clinical outcomes of their infections.
Methods: The susceptibility tests of 16 E. coli and 60 K. pneumoniae isolates, collected from
2010 to 2011, were assessed. The minimal inhibitory concentrations of eight antimicrobial
agents were assessed by the broth microdilution method according to the recommendations
of the Clinical and Laboratory Standards Institute. The detection of beta-lactamase genes
was performed by polymerase chain reaction. The genetic relatedness of these isolates was
determined by pulsed-field gel electrophoresis (PFGE) fingerprinting.
Results: The carbapenemase genes blaKPC-2 and blaOxA were detected in one and five K. pneu-
moniae isolates, respectively. The genetic combinations blaSHV-5eblaDHA and blaSHV-5eblaCTx-M-
G9 were prevalent in 45% and 26.7% of 60 K. pneumoniae isolates, respectively. The suscepti-
bility rates of 60 K. pneumoniae isolates to colistin and tigecycline were 58.3% and 50.0%,
respectively. The 30-day mortality rates of the patients treated with carbapenem, colistin,
or tigecycline were as high as 60.6%. Nine clusters of K. pneumoniae isolates were identified
by PFGE fingerprinting.Infectious Diseases, Department of Internal Medicine, Taichung Veterans General Hospital, 160,
40705, Taiwan.
(Z.-Y. Shi).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
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188 S.-R. Huang et al.Conclusion: The findings of carbapenemase genes in a few isolates and small clusters of CRE
indicated the emerging problems in the hospital. The high mortality rates were observed in
the patients treated by colistin and tigecycline, although they were the only alternative treat-
ment options for CRE infections. Active surveillance and an effective infection control strategy
should be implemented to control the spread of CRE infections.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
The global spread of carbapenem-resistant Enter-
obacteriaceae (CRE) is an alarming crisis. According to the
Study for Monitoring Antimicrobial Resistance Trends
(SMART) program (2009e2010), the ertapenem resistance
rate of Escherichia coli isolates from urinary tract infec-
tions was less than 2%.1 However, the prevalence of CRE
was as high as 31.6% in long-term acute-care facilities in
south-east Michigan, USA.2 This finding suggested that CRE
is more prevalent in high-risk groups than in the healthy
population.
Mechanisms of carbapenem resistance included car-
bapenemase production, a combination of AmpC hyper-
production and/or extended spectrum beta-lactamase
(ESBL) production, and porin mutation3 (such as ESBLs of
SHV- and CTX-M types combined with a deficiency of
OmpK35 or OmpK36 in Klebsiella pneumoniae,4,5 AmpC
overexpression and OmpC or OmpF in Enterobacter
cloacae,5 and CTX-M-type ESBL and loss of OmpC in
E. coli6). Various carbapenemases have been classified,
including class A beta-lactamases (NMC, IMI, SME, KPC,
GES), class B beta-lactamases (IMP, VIM, GIM, SPM, NDM),
and class D beta-lactamase (OXA).7 The carbapenemases
KPC-28,9 and NDM-19,10 have been reported to have been
spreading around the world since late 2000s. ST11 was
reported to be the dominant clone of KPC-2-producing
K. pneumoniae in China.11 OXA-48-producing Enter-
obacteriaceae have been reported in Europe, East-Central
Asia, and Africa.9,12
In Taiwan, the rate of ertapenem resistance in E. coli
isolates increased from 0.1% in 1999 to 1.7% in 2007.13 The
rate of ertapenem resistance (shown by disk diffusion
tests) among 2421 K. pneumoniae isolates from a Taiwa-
nese hospital in 2008 was 13.5%.14 Carbapenemases have
been detected in Enterobacteriaceae in Taiwan, such
as IMP-8 in K. pneumoniae14 and E. cloacae,15 VIM-2 in
Citrobacter freundii,15 and KPC-2 in K. pneumoniae.16
However, OXA-producing Enterobacteriaceae have not yet
been reported in Taiwan. The production of ESBL and/or
AmpC combined with a loss of porins has been reported in
Taiwan, for example the production of CMY-2 combined
with a decreased expression of OmpF and/or OmpC in
E. coli13; and the loss of OmpK36 combined with a produc-
tion of both ESBL and AmpC in K. pneumoniae17 (such as
CTX-M-14, SHV-12, and DHA-1; SHV-5 and DHA-1; SHV-12
and DHA-1; and CTX-M-14 and CMY-2). Few studies have
investigated the prevalence rate of CRE, the types of car-
bapenemase, and the outcomes of CRE infections inTaiwan. We therefore conducted this study to evaluate
these CRE-related issues.
Materials and methods
Bacterial strains
During the period January 2010 to December 2011, 8904 E.
coli and 5820 K. pneumoniae isolates were identified at the
Microbiology Laboratory of Taichung Veterans General
Hospital (TCVGH). The disk diffusion test for Enter-
obacteriaceae was read according to the 2009 recommen-
dations of the Clinical and Laboratory Standards Institute
(CLSI).18 In order to increase the possibility of identi-
fying the carbapenemase, ertapenem-resistant Enter-
obacteriaceae with a positive confirmatory test for ESBL
were not included in this study. Sixteen E. coli isolates and
60 K. pneumoniae isolates, which were resistant to erta-
penem or intermediately resistant to ertapenem on disk
diffusion tests and had negative confirmatory tests for ESBL
using the double disk diffusion method, were collected for
this study. The sources of 16 E. coli isolates included urine
(25.0%), blood (12.5%), bile (6.3%), and others (including
pus, discharge, ascites, and pleural effusion) (56.3%). The
sources of 60 K. pneumoniae isolates included urine
(21.7%), blood (18.3%), bile (18.3%), sputum (16.7%), and
others (including pus, discharge, ascites, and pleural effu-
sion) (25.0%).
Susceptibility test
The minimal inhibitory concentrations (MICs) of eight
antimicrobial agents e aztreonam, amikacin, and cefepime
(Bristol-Myers Squibb, NY, USA), imipenem (MSD, Rahway,
NJ, USA), ceftazidime (GlaxoSmithKline, Greenford, UK),
colistin (Sigma, St. Louis, MO, USA), ertapenem (MSD,
Rahway, NJ, USA) and tigecycline (Wyeth, Monza, Italy) e
were assessed using the broth microdilution method
according to the CLSI’s recommendations.19 The MICs of
colistin and tigecycline were interpreted according to the
breakpoints recommended by the 2012 European
Committee on Antimicrobial Susceptibility Testing
(EUCAST),20 while those of the other six antimicrobial
agents were read according the breakpoints recommended
by the 2012 CLSI guidelines.21 All MIC tests were performed
twice to avoid technical error. Escherichia coli ATCC 25922
and Pseudomonas aeruginosa ATCC 27853 were used as the
quality control strains.
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The modified Hodge test (MHT; using ertapenem disks) was
performed for all 76 isolates and interpreted according to
the 2012 recommendations of the CLSI.21 Positive and
negative control testing of the MHT was performed using
K. pneumoniae ATCC BAA-1705 and K. pneumoniae ATCC
BAA-1706.Molecular techniques
To carry out the polymerase chain reaction (PCR) to detect
beta-lactamase genes, bacterial DNA extraction was per-
formed using a QIAamp DNA Mini Kit (Qiagen, Hilden,
Germany). All isolates were screened for the resistance
genes encoding KPC, GES, IMP-1, IMP-2, VIM-1, AmpC, SHV,
CTX-M-Group 9 (CTX-M-G9), and OXA by PCR assay using
previously described primers (Table 1).22e27 PCR products
were sequenced for KPC-2, SHV-5, and CMY-2.Table 1 Primers used for detection of beta-lactamase genes
Enzyme Primer name
Class A carbapenemases
KPC KPC forward
KPC reverse
GES GES-C
GES-D
Class B metalloenzymes
IMP-1 IMP-1 forward
IMP-1 reverse
IMP-2 IMP-2 forward
IMP-2 reverse
VIM-1 VIM-1 forward
VIM-1 reverse
Class D oxacillinases
OXA OXA forward
OXA reverse
AmpC beta-lactamases
MOX-1, MOX-2, CMY-1, CMY-8 to CMY-11 MOXMF
MOXMR
LAT-1 to LAT-4, CMY-2 to CMY-7, BIL-1 CITMF
CITMR
DHA-1, DHA-2 DHAMF
DHAMR
ACC ACCMF
ACCMR
MIR-1T ACT-1 EBCMF
EBCMR
FOX-1 to FOX-5b FOXMF
FOXMR
ESBL
SHV-5 SHV-5F
SHV-5R
9 variants of CTX-M group CTX-M-G9 (F)
CTX-M-G9 (R)Pulsed-field gel electrophoresis (PFGE) was performed
with a contour-clamped homogeneous electric field DRII
apparatus from Bio-Rad Laboratories (Richmond, CA, USA)
as previously described.28 The chromosomal DNA was
digested overnight with XbaI (Promega, Madison, WI,
USA). DNA was electrophoresed in 1.2% SeaKem GTG
agarose (FMC, Rockland, ME, USA) at 6 V/cm for 22 hours;
the pulse time was increased from 2.2 to 54.2 seconds.
The PFGE patterns were also analyzed using the computer
software Gelcompar for Windows version 3.1b (Applied
Math, Kortrijk, Belgium). The PFGE patterns were
compared using the unweighted pair group method with
arithmetic averages clustering method by using the Dice
coefficient, according to the instructions of the Gelcom-
par manufacturer. A tolerance of 1.2% in the band position
was applied during the comparison of PFGE fingerprinting
patterns.
Multilocus sequence typing was carried out with seven
housekeeping genes (rpoB, gapA, mdh, pgi, phoE, infB, and
tonB) for K. pneumoniae. Allele sequences and sequenceSequence(5ʹ to 3ʹ) Amplicon
size (bp)
Reference
ATGTCACTGTATCGCCGTCT 893 22
TTTTCAGAGCCTTACTGCCC
GTTTTGCAATGTGCTCAACG 371 23
TGCCATAGCAATAGGCGTAG
TGAGCAAGTTATCTGTATTC 740
TTAGTTGCTTGGTTTTGATG
GGCAGTCGCCCTAAAACAAA 737
TAGTTACTTGGCTGTGATGG
TTATGGAGCAGCAACCGATGT 920
CAAAAGTCCCGCTCCAACGA
ACACAATACATATCAACTTCGC 813 24
AGTGTGTTTAGAATGGTGATC
GCTGCTCAAGGAGCACAGGAT 520 25
CACATTGACATAGGTGTGGTGC
TGGCCAGAACTGACAGGCAAA 462 25
TTTCTCCTGAACGTGGCTGGC
AACTTTCACAGGTGTGCTGGGT 405 25
CCGTACGCATACTGGCTTTGC
AACAGCCTCAGCAGCCGGTTA 346 25
TTCGCCGCAATCATCCCTAGC
TCGGTAAAGCCGATGTTGCGG 302 25
CTTCCACTGCGGCTGCCAGTT
AACATGGGGTATCAGGGAGATG 190 25
CAAAGCGCGTAACCGGATTGG
TGTTAGCCACCCTGCCGCT 825 26
GTTGCCAGTGCTCGATCAG
ATGGTGACAAAGAGAGTGCAAC 876 27
TTACAGCCCTTCGGCGATG
190 S.-R. Huang et al.types (STs) were identified at <http://www.pasteur.fr/
recherche/genopole/PF8/mlst/Kpneumoniae.html>. A dif-
ferent allele number was given to each distinct sequence
within a locus, and a distinct ST number was assigned to
each distinct combination of alleles.Survival and bacteriologic assessments
The clinical outcomes of the 76 patients with acquired
ertapenem-resistant Enterobacteriaceae isolates were
analyzed by chart review. The clinical conditions (such as
intensive care stay, ventilator use, previous stay in a nursing
home, and prior antibiotic treatment) associated with the
acquisition of ertapenem-resistant Enterobacteriaceae
isolates were reviewed. The 30-day mortality rates among
different groups of the 76 patients were analyzed by Yates’
correction of continuity and Fisher’s exact test, using the
Statistical Package for the Social Science (version 15.1; SPSS
Inc, Chicago, IL, USA). If the antibiotics (imipenem, mer-
openem, colistin, and tigecycline) were reported as active
against these isolates and were administered to patients
with ertapenem-resistant Enterobacteriaceae infection,
these patients were classified into the observation group.
None of the patients was treated with any combination of
imipenem, colistin, or tigecycline. The mortality rates of
patients treated with tigecycline, colistin, meropenem, and
imipenem were also compared. Bacteriologic eradication
was defined as a lack of growth of CRE from culture, orTable 2 The beta-lactamase genes detected in each of the ert
isolates
Genes encoding beta-lactamases Escherichia
coli (n)
None 0
Single gene
CMY-2 11
SHV-5 0
DHA 0
ACC 1
Two genes
DHA, SHV-5 0
SHV-5, CTX-M-G9 0
CTX-M-G9, CMY-2 2
SHV-5, CMY-2 1
DHA, CTX-M-G9 0
SHV-5, OXA 0
Three genes
DHA, SHV-5, CTX-M-G9 0
SHV-5, CMY-2, OXA 0
DHA, SHV-5, CTX-M-G9 0
DHA, CTX-M-G9, CMY-2 0
KPC-2, SHV-5, CTX-M-G9 0
SHV-5, CTX-M-G9, ACC 0
SHV-5, CTX-M-G9, OXA 0
SHV-5, CTX-M-G9, CMY-2 0
DHA, SHV-5, CMY-2 1
Total 16a lack of culture report due to removal of the drainage tube
on the 14th day of antibiotic treatment.
Results
The beta-lactamase genes detected in each ertapenem-
resistant E. coli and K. pneumoniae isolate are listed in
Table 2. Twenty-five isolates carried a single gene,
including blaCMY-2 in 11 E. coli and 1 K. pneumoniae
isolates, blaSHV-5 in 6 K. pneumoniae isolates, blaDHA in 6
K. pneumoniae isolates, and blaACC in 1 E. coli isolate. The
two-gene combination blaSHV-5 and blaDHA was found in 19
K. pneumoniae isolates. The combination of three genes,
blaSHV-5, blaDHA, and blaCTx-M-G9, was found in 6 K. pneu-
moniae isolates. The class D beta-lactamase gene, blaOXA,
was found in five K. pneumoniae isolates. Only one K.
pneumoniae isolate was found to carry blaKPC-2 and was
classified as ST11. A positive MHT result was found in 15
isolates (4 E. coli and 11 K. pneumoniae).
The most prevalent genes in ertapenem-resistant E. coli
and K. pneumoniae isolates are listed in Table 3. The
blaCMY-2 gene (alone or in combination with other genes)
was found in 93.8% of 16 E. coli isolates. The blaSHV-5 gene
(alone or in combination) was found in 75.0% of 60
K. pneumoniae isolates. The blaDHA gene (alone or in
combination with other genes) was found in 58.3% of 60
K. pneumoniae isolates. The combination blaSHV-5eblaDHA
(including further combination with other genes) was found
in 45% of 60 K. pneumoniae isolates. The combination,apenem-resistant Escherichia coli and Klebsiella pneumoniae
Klebsiella
pneumoniae (n)
Positive modified Hodge test
6 1 (K. pneumoniae)
1 2 (E. coli), 1 (K. pneumoniae)
6 3 (K. pneumoniae)
6 2 (K. pneumoniae)
0
19 2 (K. pneumoniae)
4
0 2 (E. coli)
0
1
1
6
3
2
1 1 (K. pneumoniae)
1 1 (K. pneumoniae)
1
1
1
0
60 15
Table 3 Prevalent gene of ertapenem-resistant Escher-
ichia coli and Klebsiella pneumoniae isolates
Genes encoding
beta-lactamases
Escherichia
coli (%)
Klebsiella
pneumoniae (%)
p
Prevalent gene, alone or in combination with other genes
CMY-2 15/16 (93.8) 6/60 (10.0) <0.001a
SHV-5 2/16 (12.5) 45/60 (75.0) <0.001b
DHA 1/16 (6.3) 35/60 (58.3) 0.001b
Prevalent genetic combination (including combination with
other genes)
SHV-5, DHA 1/16 (6.3) 27/60 (45.0) 0.010b
SHV-5,
CTX-M-G9
0 16/60 (26.7) 0.017a
a Fisher’s exact test.
b Yates’ correction of continuity.
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other genes) was found in 26.7% of 60 K. pneumoniae
isolates.
The antimicrobial susceptibilities of ertapenem-
resistant E. coli and K. pneumoniae isolates are listed in
Table 4. These 76 isolates showed moderate to high resis-
tance to aztreonam, cefepime, and ceftazidime. All 16
E. coli isolates were susceptible to amikacin, but only 40%
of the 60 K. pneumoniae isolates were susceptible to ami-
kacin. Eight (50%) of 16 E. coli isolates were susceptible to
imipenem. Fourteen (23.3%) of the 60 ertapenem-resistant
K. pneumoniae were susceptible to imipenem. The
susceptibility rates of 16 E. coli isolates to colistin and
tigecycline were 62.5% and 75.0%, respectively. The
susceptibility rates of 60 ertapenem-resistant K. pneumo-
niae to colistin and tigecycline were 58.3% and 50.0%,
respectively.
The clinical conditions associated with the acquisition of
ertapenem-resistant Enterobacteriaceae were treatment
with antibiotics (93.4%), intensive care stay (60.5%),
ventilator use (60.5%), and previous stay in a nursing home
(26.3%). A comparison of 30-day mortality among the
different groups of 76 patients who acquired ertapenem-
resistant Enterobacteriaceae is shown in Table 5. The
30-day mortality rate of all the 76 patients was 40.8%Table 4 Antibiotic susceptibility of ertapenem-resistant Escher
Antibiotics Escherichia coli (n Z 16)
MIC range
(mg/mL)
MIC50 /MIC90
(mg/mL)
Susceptibil
(%)
Amikacin 0.25e8 2/8 100
Aztreonam 2e256 32/256 12.5
Cefepime 0.5e128 16/128 43.8
Ceftazidime 64e256 256/256 0
Colistin 1e16 2/4 62.5a
Ertapenem 0.25e64 8/32 6.3
Imipenem 0.25e16 2/4 50.0
Tigecycline 0.5e4 1/2 75.0a
a According to the breakpoints recommended by EUCAST, 2012.20
MIC Z minimal inhibitory concentration.(31/76). The 7-, 14-, 30-, and 90-day mortality rates of 33
patients in the observation group were 51.5%, 51.5%, 60.6%,
72.7%, respectively (p Z 0.247). There was no significant
difference in the 30-day mortality rate between the 15
patients treated with tigecycline (73.3%) and the other 18
patients treated with colistin, imipenem, or meropenem
(73.3% vs. 50.0%; p Z 0.313). Among 33 patients in the
observation group, 20 patients had an abscess at the
infection site. Among these 20 patients, 13 patients who
underwent adequate drainage or surgical debridement had
a higher survival rate than the other seven patients who did
not (100% vs. 14.3%; p < 0.001). There was no significant
difference in the 30-day mortality rate between the group
with an imipenem MIC  1 mg/mL and the group with an
imipenem MIC  4 mg/mL (40.9% vs. 35.0%; pZ 0.852). The
bacteriologic eradication rates of tigecycline, imipenem,
and colistin on the 14th day of treatment were 66.7%, 50%,
and 25%, respectively.
The dendrograms of PFGE fingerprinting of 16 E. coli
isolates and 60 K. pneumoniae isolates are shown in Figs. 1
and 2, respectively. Nine clusters (AeI) of 60 ertapenem-
resistant K. pneumoniae isolates were identified. Each of
clusters A and B included six isolates. Each of clusters C and
D included three isolates, and each of clusters EeI included
two isolates. Two clusters (A and B) of ertapenem-resistant
E. coli isolates were identified, each cluster containing two
E. coli isolates.Discussion
The prevalence rates of ertapenem-resistant E. coli and
K. pneumoniae isolated at TCVGH (tested by the disk
diffusion method; CLSI 2009)18 from 2010 to 2011 were
0.52% and 2.97%, respectively. The prevalence rates of CRE
were lower than those of ESBL-producing Enter-
obacteriaceae. However, we were concerned that the
major source of CRE isolates was the gastrointestinal tract.
Colonization of CRE of the gastrointestinal tract could be
observed for a median of 87 days (range 60e450 days).29
CRE can spread from infected patients or hospital staff to
families and communities by household or social contact, in
contrast to the multidrug-resistant healthcare-associated,
glucose-nonfermentive pathogens harbored mainly in theichia coli and Klebsiella pneumoniae isolates
Klebsiella pneumoniae (n Z 60)
ity MIC range
(mg/mL)
MIC50 /MIC90
(mg/mL)
Susceptibility
(%)
0.25 to >256 >256/>256 40.0
1e256 32/256 6.7
1 to > 256 128/> 256 16.7
16e256 256/256 0
1e64 2/4 58.3a
0.5e256 16/128 0
0.25e256 4/16 23.3
0.5e8 1/4 50.0a
Table 5 Comparison of 30-day mortality rates among
different groups of 76 patients who acquired ertapenem-
resistant Enterobacteriaceae
Mortality (%) p
Source of culturec
Blood 8/13 (61.5) 0.173a
Sputum 4/10 (40.0) 1.000b
Urine 4/17 (23.5) 0.173a
Bile 2/12 (16.7) 0.108b
Others 13/24 (54.2) 0.173a
MIC of imipenem
1 mg/mL 9/22 (40.9) 0.852a,d
2 mg/mL 8/14 (57.1)
 4 mg/mL 14/40 (35.0)
Comparison among observation groupe
Colistin 2/4 (50.0) 1.000b
Tigecycline 11/15 (73.3) 0.313a
Imipenem 6/11 (54.5) 0.714b
Meropenem 1/3 (33.3) 0.547b
a Yates’ correction of continuity.
b Fisher’s exact test.
c The 30-day mortality rates of infections from each single
source were compared with those from all the other sources.
d The difference in the 30-day mortality rates between the
two groups, imipenem MIC  1 mg/mL and  4 mg/mL.
e The 30-day mortality rate of infections treated with each
antibiotic of the observation group was compared with those
treated by all the other antibiotics of the observation group.
MIC Z minimal inhibitory concentration.
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Figure 1. A dendrogram of pulsed-field gel electrophoresis
(PFGE) fingerprinting of 16 Escherichia coli isolates after
digestion with XbaI.
192 S.-R. Huang et al.hospital environments. The example of ESBL-producing
Enterobacteriaceae in the past 10 years indicates that
CRE may rapidly reach a high rate worldwide6 and result in
a crisis of treatment failure.
The zone diameters of 12 isolates (5 E. coli and 7
K. pneumoniae) were interpreted as intermediately
resistant to ertapenem by the microbiology laboratory at
TCVGH according to breakpoints (susceptible, 19 mm;
intermediately resistant, 16e18 mm; resistant, 15 mm)
recommended by the CLSI (2009).18 However, ertapenem
MICs for all these 12 isolates were  1 mg/m (range
1e32 mg/mL) and were read as resistant according to
breakpoints recommended by the CLSI (2012).21 If the
breakpoints of disk diffusion were updated according to
the 2012 CLSI recommendations21 (susceptible,  23 mm;
intermediately resistant, 20e22 mm; resistant,  19 mm),
the results of disk diffusion tests for these isolates would
be read as resistant. Therefore, the susceptibility
measurements would be consistent for the disk diffusion
test and broth microdilution method. The ertapenem MICs
for two additional isolates were 0.25 and 0.5 mg/mL,
respectively, andwere interpreted as susceptible according
to breakpoints recommended by the CLSI (2012).21 The
beta-lactamase gene(s), MHT, and treatment outcomes for
these two isolates were: CMY-2, positive MHT, treatment
failure for the first one; and SHV-5, CTX-M-G9, and ACC,
negative MHT, treatment failure for the second one.
Due to the complexity of the resistance mechanisms,
CRE may exhibit a wide range of MICs for carbapenem,
including some with only low levels of carbapenem resis-
tance.3 Intermediate susceptibility and even susceptibility
to carbapenems have been observed for producers of all
types of carbapenemase.30 There is no consensus on the
cut-off value of MICs of carbapenems that should be
applied for research into carbapenemase activity.30 The
criteria for ertapenem resistance had not been clearly
established by microbiologic (mechanisms and breakpoints)
and clinical data, so these two isolates were included in
this study.
The most prevalent genes were blaCMY-2 in 93.8% of 16 E.
coli isolates, and blaSHV-5 in 75% of 60 K. pneumoniae
isolates. Most isolates harbored combination genes, such as
blaSHV-5 and blaDHA in 45% of 60 K. pneumoniae isolates, and
blaSHV-5 and blaCTx-M-G9 in 26.7% of 60 K. pneumoniae
isolates in this study. The bla genes associated with car-
bapenem resistance are complex. The bla genes of 16
blaKPC-2-producing K. pneumoniae strains that have spread
worldwide were analyzed.8 These harbored a natural
chromosome-encoded bla gene [blaSHV-1 ([12.5%), blaSHV-11
(68.7%), or blaOKP-A/B (18.8%)] and several acquired and
plasmid-encoded genes [blaTEM-1 (81.3%), blaCTx-M-2 (31.3%),
blaCTx-M-12 (12.5%), blaCTx-M-15 (18.7%), and blaOxA-9
(37.5%)]. The blaKPC-2 gene was always associated with one
of the Tn4401 isoforms (a, b, or c). The complexity of beta-
lactamase genes harbored in carbapenem-resistant isolates
makes the phenotype-based identification of carbapenem
resistance more difficult.
One K. pneumoniae isolate that carried the blaKPC-2 gene
was classified as ST11. It was isolated from a patient who
had been hospitalized in China. The dominant clone (ST11)
of KPC-producing K. pneumoniae isolates was identified as
originating from Zhejiang province (4 hospitals in Hangzhou
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Figure 2. A dendrogram of pulsed-field gel electrophoresis (PFGE) fingerprinting of 60 Klebsiella pneumoniae isolates after
digestion with XbaI.
Carbapenem-resistant E. coli and K. pneumoniae 193and 1 hospital in Ningbo), Jiangsu province (1 hospital in
Nanjing) and Anhui province (1 hospital in Hefei) in China.11
Early identification of the KPC-producing K. pneumoniae
isolates from patients linked epidemiologically with these
endemic hospitals in Chinese cities is mandatory to control
the spread.Mechanisms of carbapenem resistance include carbape-
nemase production,7e10 combination of AmpC-
hyperproduction and/or extended spectrum beta-
lactamase (ESBL)-production, and porin mutation.3e6
Enterobacteriaceae with ESBL production and porin muta-
tion have been identified in Taiwan.13,17 According to the
194 S.-R. Huang et al.report from the microbiology laboratory at TCVGH from
2010 to 2011, 12 (26%) of 46 ertapenem-resistant E. coli
isolates had a positive confirmatory test for ESBL; 34 (20%)
of 173 ertapenem-resistant K. pneumoniae isolates had
a positive confirmatory test for ESBL.
To increase the possibility of identifying the carbape-
nemase, ertapenem-resistant Enterobacteriaceae with
a positive confirmatory test for ESBL were not included in
this study. The selection of Enterobacteriaceae with
a positive screening test and negative confirmatory test for
ESBL did not indicate that Enterobacteriaceae with ESBL
genes and porin mutation were excluded. In this study,
56.7% of 60 K. pneumoniae isolates with a positive
screening test and negative confirmatory test for ESBL
harbored ESBL genes as well as ampC genes. Similarly,
results from the SENTRY Asia-Pacific Surveillance Program
showed that 57% of 51 K. pneumoniae with a positive
screening test and negative confirmatory test for ESBL
harbored a combination of ESBL and plasmid-borne AmpC
enzyme of the CIT or DHA type.31 For the Enter-
obacteriaceae isolates carrying both the ESBL and AmpC
enzymes, the phenotype appeared to be a positive
screening test and a negative confirmatory test. The AmpC
enzyme can hydrolyze clavulanic acid, and thus make the
confirmatory test negative.32
Among the 15 isolates with a positive MHT result, only
one isolate harbored a carbapenemase gene, the blaKPC-2
gene. One isolate was negative on PCR. The other 13
isolates harbored the blaESBL gene(s), blaAmpC gene(s), or
both types of gene. It is important to be aware of false-
positive results when interpreting the MHT.33,34 The sensi-
tivity and specificity of the MHT for detecting carbapene-
mase were 77.4% and 38.9% in 54 carbapenemase and/or
ESBL/AmpC-producing Enterobacteriaceae isolates,
respectively, in one previous study.33 False-positive MHT
results could result from the production of ESBL or
ampC.33,34 Five isolates were found to contain the blaOxA
gene. Since OXA-48 was first detected in K. pneumoniae
isolates in Turkey in 2003, OXA-48-producing Enter-
obacteriaceae have spread worldwide.9,12 Acinetobacter
baumannii isolates with OXA-23, OXA-24, OXA-51, and OXA-
58 have been reported in Taiwan.35 However, Enter-
obacteriaceae with a blaOxA gene have never been reported
in Taiwan. Therefore, sequencing of the blaOxA gene is
needed to identify the types of blaOxA gene present.
The susceptibility rates of 60 ertapenem-resistant K.
pneumoniae to colistin and tigecycline were 58.3% and
50.0%, respectively, in this study. The susceptibility
patterns of CRE to colistin and tigecycline varied in
different strains.36 Susceptibility tests on 81 CRE isolates
from the UK were performed using the agar dilution method
recommended by the CLSI.36 Chloramphenicol, cipro-
floxacin, and nitrofurantoin inhibited less than 25% of
isolates, whereas colistin was active against 75/81 isolates
(92.6%), and tigecycline was active against 38/81 isolates
(46.9%).36 The MICs of ertapenem and imipenem against K.
pneumoniae isolates showed a range from 0.5 to 256 mg/mL
and 0.25 to 256 mg/mL, respectively, in this study. The
range of carbapenem MIC for 49 CRE strains from China with
different resistance mechanisms has been reported.37
Moderate- to high-level carbapenem resistance in most
isolates is more closely associated with a loss or decreasedexpression of both major porins combined with the produc-
tion of AmpC or ESBL, while KPC-2, IMP-4, and IMP-8 carba-
penemase production may lead to a low to moderate level of
carbapenem resistance in Enterobacteriaceae in China.37
There was no significant difference between the
mortality rates of the group who acquired CRE susceptible
to imipenem and those who acquired CRE resistant to imi-
penem (p Z 0.852). Patients in the observation group
showed poor survival. In contrast, removal of the focus of
infection (by debridement or drainage of the abscess) was
associated with good survival. In a recent case-control
study on the outcomes of carbapenem-resistant K. pneu-
moniae infection, removal of the focus of infection focus by
an adjunctive procedure (i.e., debridement, drainage, or
removal of the catheter) was associated with patient
survival [odds ratio (OR) 0.14, 95% confidence interval (CI)
0.04e0.49; p Z 0.002].38 The administration of antibiotics
with in vitro activity against carbapenem-resistant K.
pneumoniae was not associated with patient survival (OR
2.3, 95% CI 0.73e7.24; p Z 0.15).38 Although the patients
treated with tigecycline had higher bacteriologic eradica-
tion rates, there was no significant difference in the 30-day
mortality rate between these patients and the other
patients in the observation group. The causes of mortality
could be attributed to inadequate debridement or
drainage, severity, and patient co-morbidity. If patients
were stratified according to infection site, severity, and co-
morbidity, the number in each group would be too small to
provide data of adequate sample size for the statistical
analysis in this study. However, this study focused on the
overview of clinical outcome rather than an analysis of risk
factors for mortality.
The PFGE patterns of 60 K. pneumoniae isolates were
relatively diverse, since some strains could have originated
from different ancestors. This indicated that the Enter-
obacteriaceae could acquire a resistance gene from hori-
zontal transfer of mobile genetic elements carrying
a resistance gene (such as a plasmid or transposon). The
fact that several clusters of ertapenem-resistant Enter-
obacteriaceae isolates were identified indicated that they
had spread in the hospital via contacts. Appropriate strat-
egies should be implemented to limit the spread of these
pathogens, including active surveillance of patients with
epidemiologic links to persons from whom CRE have been
recovered, especially for high-risk groups (those with prior
antibiotic treatment, an intensive care stay, ventilator use,
or a previous stay in a nursing home). However, the cost-
effectiveness of active surveillance remains to be
explored.
In conclusion, two carbapenemase genes, blaKPC-2 and
blaOxA, were identified in carbapenem-resistant K. pneu-
moniae isolates. Other carbapenemase genes such as
blaGES, blaIMP, and blaVIM were not detected. The genetic
combinations blaSHV-5eblaDHA and blaSHV-5eblaCTx-M-G9 were
prevalent in K. pneumoniae isolates. The mortality rates of
patient-acquired ertapenem-resistant Enterobacteriaceae
infection were high. Removal of the focus of infection (by
debridement or drainage of the abscess) was associated
with good survival. The findings of carbapenemase genes in
a few isolates and small clusters of CRE indicated emerging
problems at the hospital. Appropriate strategies should be
implemented to control the spread of CRE.
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